DCGO Relative Valuation
DCGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DCGO is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for DCGO's competitors is 22.08, providing a benchmark for relative valuation. DocGo Inc Corp (DCGO) exhibits a P/S ratio of 0.46, which is -97.91% above the industry average. Given its robust revenue growth of -50.01%, this premium appears unsustainable.
People Also Watch
CYH
Community Health Systems Inc
4.210
USD
+0.96%
TBPH
Theravance Biopharma Inc
9.450
USD
+0.64%
MEI
Methode Electronics Inc
7.520
USD
+1.21%
ATXS
Astria Therapeutics Inc
4.290
USD
+0.70%
METC
Ramaco Resources Inc
9.260
USD
+1.20%
GRPN
Groupon Inc
26.570
USD
+0.34%
HAIN
Hain Celestial Group Inc
2.090
USD
+0.97%
FLX
BingEx Ltd
2.320
USD
+2.65%
ORGO
Organogenesis Holdings Inc
3.260
USD
+0.93%
CYD
China Yuchai International Ltd
17.710
USD
+0.51%
FAQ
Is DocGo Inc (DCGO) currently overvalued or undervalued?
DocGo Inc (DCGO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.46 is considered Undervalued compared with the five-year average of 1.11. The fair price of DocGo Inc (DCGO) is between 16.48 to 19.46 according to relative valuation methord. Compared to the current price of 1.39 USD , DocGo Inc is Undervalued By 91.57% .
What is DocGo Inc (DCGO) fair value?
How does DCGO's valuation metrics compare to the industry average?
What is the current P/B ratio for DocGo Inc (DCGO) as of May 21 2025?
What is the current FCF Yield for DocGo Inc (DCGO) as of May 21 2025?
What is the current Forward P/E ratio for DocGo Inc (DCGO) as of May 21 2025?